top of page
Search

New AusBiotech report shows increasing US investment in Australian biotechs


Australia continues to attract significant investment from US investors, with the total figure of US investment into Australian life science companies totaling US1.43 billion and a strong growth trend over the five-year period, between 2018-2022.


An analysis of investment data by AusBiotech shows 100 deals between US-based investors and Australian-headquartered life sciences companies over the analysis period.


Fourteen deals totaling US$139.058 million were reported in 2018, 21 deals totaling US$229.269 million in 2019, 15 deals totaling US$125.619 million in 2020, 26 deals totaling US$294.75 million in 2021, and 24 deals totaling US$642.341 million in 2022.


The data includes both private and ASX-listed companies across the following subsectors: biotech, therapeutics, drug discovery, and medtech/medical devices; digital health; medical imaging and monitoring/sensors; surgical, dental and other medical devices; and agribiotech companies, including bio-based products, medicines for animal health, microbial technology, feed supplements to reduce methane emissions, and technologies.


Read more:


コメント


Better Living Showcase acknowledges the Traditional Owners of the land on which we live and work – Noongar Boodjar. We acknowledge their connection to this Country and pay our respect to Elders past and present.

  • Instagram
  • Facebook
  • LinkedIn
  • YouTube

© 2024 Better Living Showcase. All Rights Reserved.

​

1800 984 880

Powered by

static1.squarespace.png
bottom of page